LimmaTech Biologics AG is a clinical stage biopharmaceutical company. We are a science-driven firm focused on the development and manufacture of next generation pharmaceuticals. We are at the forefront of in vivo carbohydrate engineering. LimmaTech applies its expertise in translating novel scientific concepts into early proof of concepts for both the prevention and treatment of life-threatening diseases.

Our proprietary programs include the development of the CustomGlycan Platform, a technology for producing monoclonal antibodies with improved functionality through glycosylation. In addition, we develop vaccines together with GlaxoSmithKline plc under an exclusive research and development agreement.